Evidence map›Paper›PMID 32209114›Full record

ArticleJournal of nanobiotechnology2020

Porous gold nanoparticles for attenuating infectivity of influenza A virus.

Jinyoung Kim, Minjoo Yeom, Taeksu Lee, Hyun-Ouk Kim, Woonsung Na, Aram Kang, Jong-Woo Lim, Geunseon Park, Chaewon Park, Daesub Song and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Nanoscale Interaction Mechanisms of Antiviral Activity.ACS pharmacology & translational science · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Jinyoung KimDepartment of Chemical and Biomolecular Engineering, Yonsei University, Yonsei-ro 50, Seoul, 120-749, Republic of Korea.
Minjoo YeomDepartment of Pharmacy, Korea University College of Pharmacy, Sejong-ro 2511, Sejong, 30019, Republic of Korea.
Taeksu LeeDepartment of Nano Manufacturing Technology, Korea Institute of Machinery and Materials (KIMM), 156 Gajeongbuk-Ro, Yuseong-Gu, Daejeon, 34103, Republic of Korea.
Hyun-Ouk KimDepartment of Pharmacy, Korea University College of Pharmacy, Sejong-ro 2511, Sejong, 30019, Republic of Korea.
Woonsung NaCollege of Veterinary Medicine, Chonnam National University, Yongbong-ro 77, Buk-Gu, Gwangju, South Korea.
Aram KangDepartment of Pharmacy, Korea University College of Pharmacy, Sejong-ro 2511, Sejong, 30019, Republic of Korea.
Jong-Woo LimDepartment of Chemical and Biomolecular Engineering, Yonsei University, Yonsei-ro 50, Seoul, 120-749, Republic of Korea.
Geunseon ParkDepartment of Chemical and Biomolecular Engineering, Yonsei University, Yonsei-ro 50, Seoul, 120-749, Republic of Korea.
Chaewon ParkDepartment of Chemical and Biomolecular Engineering, Yonsei University, Yonsei-ro 50, Seoul, 120-749, Republic of Korea.
Daesub SongDepartment of Pharmacy, Korea University College of Pharmacy, Sejong-ro 2511, Sejong, 30019, Republic of Korea. sds1@korea.ac.kr.
Seungjoo HaamDepartment of Chemical and Biomolecular Engineering, Yonsei University, Yonsei-ro 50, Seoul, 120-749, Republic of Korea. haam@yonsei.ac.kr.ORCID http://orcid.org/0000-0002-4990-0523
Yonsei University · KRKorea University · KRChonnam National University · KRKorea Institute of Machinery & Materials · KR

Funding

National Research Foundation of Korea 2018M3A9H4056340
6 · The paper itself

Abstract

backgroundInfluenza viruses (IVs) have become increasingly resistant to antiviral drugs that target neuraminidase and matrix protein 2 due to gene mutations that alter their drug-binding target protein regions. Consequently, almost all recent IV pandemics have exhibited resistance to commercial antiviral vaccines. To overcome this challenge, an antiviral target is needed that is effective regardless of genetic mutations. MAIN BODY: In particular, hemagglutinin (HA), a highly conserved surface protein across many IV strains, could be an effective antiviral target as it mediates binding of IVs with host cell receptors, which is crucial for membrane fusion. HA has 6 disulfide bonds that can easily bind with the surfaces of gold nanoparticles. Herein, we fabricated porous gold nanoparticles (PoGNPs) via a surfactant-free emulsion method that exhibited strong affinity for disulfide bonds due to gold-thiol interactions, and provided extensive surface area for these interactions. A remarkable decrease in viral infectivity was demonstrated by increased cell viability results after exposing MDCK cells to various IV strains (H1N1, H3N2, and H9N2) treated with PoGNP. Most of all, the viability of MDCK cells infected with all IV strains increased to 96.8% after PoGNP treatment of the viruses compared to 33.9% cell viability with non-treated viruses. Intracellular viral RNA quantification by real-time RT-PCR also confirmed that PoGNP successfully inhibited viral membrane fusion by blocking the viral entry process through conformational deformation of HA.

conclusionWe believe that the technique described herein can be further developed for PoGNP-utilized antiviral protection as well as metal nanoparticle-based therapy to treat viral infection. Additionally, facile detection of IAV can be achieved by developing PoGNP as a multiplatform for detection of the virus.

Indexed as

AnimalsAntiviral AgentsDogsGoldInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H9N2 SubtypeMadin Darby Canine Kidney CellsMembrane FusionMetal NanoparticlesPorosityRNA, ViralVirus InternalizationAntiviral AgentsGoldRNA, ViralDisulfide bondInfluenza A virusMembrane fusionPorous gold nanoparticleVirus inactivation

Identifiers

PMID32209114
PMCPMC7092597
OpenAlexW3013272913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.